Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Cancer Genetics (CGIX)

Add to Watchlists
Create an Alert
15.69 -0.68  -4.15% NASDAQ Apr 24, 3:14PM BATS Real time Currency in USD
View Full Chart
CGIX Price Chart
View All Performance Charts

CGIX Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Cancer Genetics is up 39.47% over the last year vs S&P 500 Total Return up 21.58%, Icon up 46.89%, and Quintiles Transnational up N/A.

Get Quote for

Portfolio Strategies Featuring CGIX

Did Cancer Genetics make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

CGIX Profile

  • Sector: Healthcare
  • Industry: Diagnostics & Research
  • Headquarters Country: United States
  • Headquarters State/Province: New Jersey
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Electromedical and Electrotherapeutic Apparatus Manufacturing
  • NAICS Code: 334510
  • NAICS Industry: Navigational, Measuring, Electromedical, and Control Instruments Manufacturing
  • NAICS Industry Code: 3345
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 33

Cancer Genetics, Inc. develops and commercializes proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer.

Recent Quotes

Symbol Price Chg Chg % Market Cap
CGIX 15.69 -0.68 -4.15% 145.53M
Create Watchlist from Quotes

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.